Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)

被引:23
|
作者
Xu, Yanyan [1 ,2 ]
Egido, Estefania [1 ,3 ,4 ]
Li-Blatter, Xiaochun [1 ]
Mueller, Rita [1 ]
Merino, Gracia [3 ,4 ]
Berneche, Simon [1 ,2 ]
Seelig, Anna [1 ]
机构
[1] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland
[2] Swiss Inst Bioinformat, CH-4056 Basel, Switzerland
[3] Univ Leon, INDEGSAL, E-24071 Leon, Spain
[4] Univ Leon, Fac Vet, Dept Biomed Sci Physiol, E-24071 Leon, Spain
基金
瑞士国家科学基金会;
关键词
BRAIN-BARRIER PERMEATION; MULTIDRUG-RESISTANCE; ATPASE ACTIVITY; DRUG TRANSPORT; SUBSTRATE RECOGNITION; STRUCTURAL BASIS; PLASMA-MEMBRANE; LIVING CELLS; SITES; ACTIVATION;
D O I
10.1021/acs.biochem.5b00649
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ATP binding cassette (ABC) transporters ABCG2 and ABCB1 perform ATP hydrolysis-dependent efflux of structurally highly diverse compounds, collectively called allocrites. Whereas much is known about allocrite-ABCB1 interactions, the chemical nature and strength of ABCG2-allocrite interactions have not yet been assessed. We quantified and characterized interactions of allocrite with ABCG2 and ABCB1 using a set of 39 diverse compounds. We also investigated potential allocrite binding sites based on available transporter structures and structural models. We demonstrate that ABCG2 binds its allocrites from the lipid membrane, despite their hydrophilicity. Hence, binding of allocrite to both transporters is a two-step process, starting with a lipid water partitioning step, driven mainly by hydrophobic interactions, followed by a transporter binding step in the lipid membrane. We show that binding of allocrite to both transporters increases with the number of hydrogen bond acceptors in allocrites. Scrutinizing the transporter translocation pathways revealed ample hydrogen bond donors for allocrite binding. Importantly, the hydrogen bond donor strength is, on average, higher in ABCG2 than in ABCB1, which explains the higher measured affinity of allocrite for ABCG2. pi-pi stacking and pi-cation interactions play additional roles in binding of allocrite to ABCG2 and ABCB1. With this analysis, we demonstrate that these membrane-mediated weak electrostatic interactions between transporters and allocrites allow for transporter promiscuity toward allocrites. The different sensitivities of the transporters to allocrites' charge and amphiphilicity provide transporter specificity. In addition, we show that the different hydrogen bond donor strengths in the two transporters allow for affinity tuning.
引用
收藏
页码:6195 / 6206
页数:12
相关论文
共 50 条
  • [21] Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs)
    Hofman, Jakub
    Kucera, Radim
    Neumanova, Zuzana
    Klimes, Jiri
    Ceckova, Martina
    Staud, Frantisek
    XENOBIOTICA, 2016, 46 (05) : 416 - 423
  • [22] Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation
    van Hoppe, Stephanie
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    PHARMACOLOGICAL RESEARCH, 2017, 120 : 43 - 50
  • [23] Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study
    Mahamadou Tandia
    Asma Mhiri
    Bernard Paule
    Raphaël Saffroy
    Valérie Cailliez
    Gaëlle Noé
    Robert Farinotti
    Laurence Bonhomme-Faivre
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 759 - 766
  • [24] Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study
    Tandia, Mahamadou
    Mhiri, Asma
    Paule, Bernard
    Saffroy, Raphael
    Cailliez, Valerie
    Noe, Gaelle
    Farinotti, Robert
    Bonhomme-Faivre, Laurence
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 759 - 766
  • [25] Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
    Tang, Seng Chuan
    Nguyen, Luan N.
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (06) : 1484 - 1494
  • [26] Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, Is a Substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2)
    Shen, H.
    Lee, F. Y.
    Gan, J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 337 (02): : 423 - 432
  • [27] Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)
    Kort, Anita
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    PHARMACOLOGICAL RESEARCH, 2015, 102 : 200 - 207
  • [28] P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) restrict the brain penetration of the Janus family of tyrosine kinase (JAK) inhibitor CYT387
    Durmus, Selvi
    Xu, Ning
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    FASEB JOURNAL, 2013, 27
  • [29] Insight into the Cooperation of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) at the Blood-Brain Barrier: A Case Study Examining Sorafenib Efflux Clearance
    Agarwal, Sagar
    Elmquist, William F.
    MOLECULAR PHARMACEUTICS, 2012, 9 (03) : 678 - 684
  • [30] P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice
    Wang, Jing
    Gan, Changpei
    Retmana, Irene A.
    Sparidans, Rolf W.
    Li, Wenlong
    Lebre, Maria C.
    Beijnen, Jos H.
    Schinkel, Alfred H.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 556 : 172 - 180